Overview of KAHF Technology: A solution for early stage Cancer Patients and Metastatic Patients. KAHF Technology is capable of metastasis inhibition in early stage PDAC supported with extensive pre-clinical data and further sensitizes hard-to-treat metastatic tumor cells to standard-of-the-care therapy.
Author Archive
Muhammad Sadeqi Nezhad is a cancer researcher at Clinical and Translational Science Institute (CTSI), University of Rochester Medical Center, New York, USA. Currently, he is working with a great team on development of cancer therapeutics for pancreatic cancer patients with primary and metastatic tumors at Wilmot Cancer Institute. One of his research desires is […]